Document is current
Any future updates will be listed below
-
Authors
Bittar, Mohamad https://orcid.org/0000-0001-9283-7462
Merjanah, Sali https://orcid.org/0000-0002-5440-0961
Alkilany, Reem https://orcid.org/0000-0001-5589-9760
Magrey, Marina https://orcid.org/0000-0002-6520-5619
- License Information
-
More Information
Article History
Received: 17 January 2022
Accepted: 27 April 2022
First Online: 30 June 2022
Declarations
:
: This project and its methods/protocols received the MetroHealth system institutional review board approval (IRB19-00404). Institution: The MetroHealth system, Cleveland, OH. Access to the IBM Explorys database was granted by the MetroHealth institutional review board and informatics department. All methods were carried out in accordance with relevant guidelines and regulations. Waived or not applicable due to the nature of the study (de-identified clinical database). This has been determined by the MetroHealth system institutional review board.
: Not applicable.
: MB: no conflict of interest. SM: no conflict of interest. RA: no conflict of interest. MM: Grants: Abbvie and UCB Pharma. Consulting fees: Novartis. Payment or honoraria: Novartis, UCB Pharma, Abbvie and Eli Lilly.
